Chester County News and Community Website
GLENOLDEN, PA — The Charcot-Marie-Tooth Association | Strategy to Accelerate Research (CMTA|STAR) announced a venture philanthropy grant to Taysha Gene Therapies (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused …
Read More
EXTON, PA — Castle Creek Biosciences, Inc. recently announced a research collaboration with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of …
Read More
PHILADELPHIA, PA — Amicus Therapeutics, Inc. (Nasdaq: FOLD) announced its intent to launch a next-generation genetic medicine company, Caritas Therapeutics, Inc., through a definitive business combination agreement pursuant to which …
Read More
PHILADELPHIA, PA — Scout Bio recently announced the successful completion of a CKD-associated anemia study in client-owned cats treated with SB-001, an AAV expressing feline erythropoietin (fEPO). The study demonstrated …
Read More
HATBORO, PA — Azzur Labs, an Azzur Group company, this week announced the establishment of its latest operation, based in Chicago under the leadership of Cecil Runyon, Senior Director. The …
Read More
WAYNE, PA — XyloCor Therapeutics announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial (EXACT) of XC001 (encoberminogene rezmadenovec), its lead investigational gene therapy …
Read More
PHILADELPHIA, PA — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or …
Read More
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who …
Read More